is tirzepatide a glp 1 (GLP-1 / GIP) GLP-1 use tripled among non-diabetics,

ACS Appl Mater Interfaces

Sitagliptin Plus Metformin vs

If this patient increases the dose to 15 mg (purple curve), then (a) increasing the dosing interval to 10 days reduces cost by 30% and maintains identical weight loss and (b) increasing the dosing interval to 14 days reduces cost by 50% and maintains 87% weight loss Figure 3D concerns a patient on 15 mg q1wk and shows that they can cut their costs in half and retain 79% of their weight loss

Serre, V

The variability in available studies, potential confounding factors, and the severe heterogeneity of conclusions all emphasize the need for more high-quality evidence-based primary research to optimize perioperative management of patients taking GLP-1 RAs

Unlike traditional GLP1 receptor agonists, tirzepatide is more selective for the GIP receptor, resulting in a more balanced activation of these receptors